23andMe breach targeted Chinese, Jewish populations

Off Biotech, biotechnology, Business, cancer, Congress, drug development, drug prices, drug pricing, FDA, finance, genetics, government agencies, Health, Human Health, legal, Life Sciences, Medicine, Pharma, Pharmaceuticals, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hey there. Today, we discuss how Medicaid might pay for the costly but potentially curative sickle cell gene therapies, as well as the shocking lawsuit that outlines a data breach at 23andMe that targets Chinese and Jewish customers.

Read the rest…

Read Original Article: 23andMe breach targeted Chinese, Jewish populations »

About The Author